Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma

Table 1 Clinical characteristics of the subjects in this study

Group	No	Age (yr)	Sex (M/F)	TB (mg/dl)	ALT (IU/L)	Alb (g/l)	AP (IU/L)
Controls	50	34.6 ± 10.3a	29/21	-	-	-	-
CH	61	42.0 ± 13.0a	46/15	1.6 ± 0.9a	98.1 ± 72.9	3.8 ± 0.3	201.5 ± 106.2a
Cirrhosis	37	50.0 ± 13.3a	26/11	2.5 ± 1.3a	65.0 ± 49.6	3.3 ± 0.5	290.2 ± 212.5a
HCC	59	53.0 ± 12.0a	50/9	3.0 ± 2.1a	79.9 ± 46.1	3.4 ± 0.3	612.9 ± 393.7
CCA	69	60.2 ± 12.6	46/23	7.5 ± 7.6	71.4 ± 68.7	3.4 ± 0.5	894.3 ± 850.2

Controls = healthy blood donors, CH = chronic hepatitis, HCC = hepatocellular carcinoma, CCA = cholangiocarcinoma. TB = total bilirubin, ALT = alanine aminotransferase, Alb = albumin, AP = alkaline phosphatase. Data were expressed as mean ± standard deviation. Statistical analysis compared to CCA:

^aP < 0.05.